Scientists behind COVID-19 vaccine will depart BioNTech

The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech founders plan exit to set up new venture, shares slump

By Ludwig Burger and Patricia Weiss FRANKFURT, March 10 (Reuters) - BioNTech's two co-founders and leading executives will ...

Co-founders behind pioneering Covid vaccine to step down from BioNTech

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...

BioNTech shares fall after co-founders plan exit and outlook misses forecasts

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.
Fierce Biotech

BioNTech's CEO, CMO prep departure to set up next-gen mRNA company

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

COVID-19 vaccine pioneers to leave BioNTech and focus on mRNA

Uğur Şahin and Özlem Türeci, a Turkish husband-and-wife team, became unlikely celebrities during the pandemic for their world ...

BioNTech falls on outlook, departure of co-founders

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...
Medical Dialogues

BioNTech Founders Ugur Sahin, Oezlem Tuereci to Exit by 2026 to Launch New mRNA Venture

Frankfut: The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end ...

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by ...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA ...
Seeking Alpha

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...